As the results shown (Figure 4(a)), the high NAGs group has obvious cell cycle changes (including E2F targets and G2M checkpoint pathways), tumor aggression (including MYC targets V1 and MYC targets V2 pathways), and immune suppression (including WNT beta catenin signaling pathways) related pathway activation, while the low NAGs group was with more pathway involving immune activation, including interferon alpha response, interferon gamma response, IL2 STAT5 signaling pathway, inflammatory response, and complement activation pathways [30–32]. The gene discussed is CTNNB1; the disease is neoplasm.